We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
- Authors
Hou, Aohan; Hou, Kaiyu; Huang, Qiubo; Lei, Yujie; Chen, Wanling
- Abstract
Immune checkpoint inhibitors (ICIs) are starting to transform the treatment for patients with advanced cancer. The extensive application of these antibodies for various cancer obtains exciting anti-tumor immune response by activating T cells. Although the encouraging clinical benefit in patients receiving these immunostimulatory agents are observed, numbers of patients still derive limited response or even none for reasons unknown, sometimes at the cost of adverse reactions. Myeloid-derived suppressor cells (MDSCs) is a heterogeneous immature population of myeloid cells partly influencing the efficacy of immunotherapies. These cells not only directly suppress T cell but mediate a potently immunosuppressive network within tumor microenvironment to attenuate the anti-tumor response. The crosstalk between MDSCs and immune cells/non-immune cells generates several positive feedbacks to negatively modulate the tumor microenvironment. As such, the recruitment of immunosuppressive cells, upregulation of immune checkpoints, angiogenesis and hypoxia are induced and contributing to the acquired resistance to ICIs. Targeting MDSCs could be a potential therapy to overcome the limitation. In this review, we focus on the role of MDSCs in resistance to ICIs and summarize the therapeutic strategies targeting them to enhance ICIs efficiency in cancer patients.
- Subjects
IMMUNE checkpoint inhibitors; SUPPRESSOR cells; T cells; CELL populations; TUMOR microenvironment; CYTOTOXIC T lymphocyte-associated molecule-4; PROGRAMMED death-ligand 1
- Publication
Frontiers in Immunology, 2020, Vol 11, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2020.00783